Skip to content

Natural History of Sickle Cell Disease

Studies of the Natural History of Sickle Cell Disease

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00081523
Enrollment
3500
Registered
2004-04-15
Start date
2004-04-29
Completion date
Unknown
Last updated
2026-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain Crisis

Keywords

Hemoglobin, Acute Chest Syndrome, Treatment Options, Nitric Oxide, Pulmonary Hypertension, Natural History

Brief summary

This study is not a treatment protocol and no experimental treatments are involved. Study participants may be seen as needed for clinical, translational and basic research studies, or as medically indicated. Subjects will receive their general medical care outside the NIH and will be seen at our clinic or at CNHS with varying frequency. Subjects may be seen for multiple visits. Subjects may be asked to return for additional testing as needed. Clinical care for patients with sickle cell disease will be provided as appropriate through the Sickle Cell Clinic and the inpatient clinical center.

Detailed description

This protocol will permit the establishment of a repository of biospecimens from individuals affected with sickle cell disease to identify and evaluate underlying disease mechanism(s), and to facilitate understanding of the pathogenesis and natural history of vaso-occlusive painful crisis and other complications of the disease. Patients will be evaluated with a medical history and physical examination and routine laboratory studies will be obtained as needed to assess diagnosis, disease activity, and disease complications and to monitor for treatment-related responses and toxicities. This protocol may also provide for the continued storage and analysis of clinical and research data, and biospecimens previously obtained from other NIH Institutional Review Board (IRB)-approved protocols with subject consent. Patients eligible for other research protocols will be offered an opportunity to participate in these studies after signed informed consent has been obtained. Apart from such protocols, any medical care or additional tests/investigations recommended or provided to the patient will be consistent with routine standards of practice and will be provided in consultation with the patient s referring physician.

Interventions

None listed

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
Lead SponsorNIH

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
2 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* INCLUSION CRITERIA: * Individuals with known or suspected sickle cell disease * 2 years of age and older * Willing to provide informed consent or appropriate informed consent from parent or legal guardian * Patients seen at sickle outpatient clinics at any one of the participating centers (CNHS or NIH).

Exclusion criteria

* Patient and/or guardian unable and unwilling to give informed consent or assent. * Patients less than 2 years of age. Individuals with known or suspected sickle cell disease will meet the inclusion criteria to enroll in this protocol and can undergo study activities. However, if the individual is found not to have sickle cell disease after enrollment, they will be removed from the protocol, and their research samples will be discarded but they will be counted toward the study accrual. The study team will notify the individual about their removal from the study and explain the reason for it. Any necessary regulatory reporting will also be completed.

Design outcomes

Primary

MeasureTime frameDescription
To gather, through clinical experience, information regarding the natural history, co-morbid conditions and outcomes, and complications relating to sickle cell disease and other hemolytic disorders in minority/ethnic patientsongoingBetter characterization of the natural history of sickle cell disease

Countries

United States

Contacts

CONTACTNancy A Asomaning
nancy.asomaning@nih.gov(301) 605-0398
PRINCIPAL_INVESTIGATORSwee Lay Thein, M.D.

National Heart, Lung, and Blood Institute (NHLBI)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 17, 2026